In partnership with
Private Investor Webinar
Changing the Future of Alzheimer's Through Earlier Detection
An investment-led webinar on the growing commercial opportunity in early Alzheimer's detection.
Earlier disease detection is becoming one of healthcare's most important commercial and clinical priorities.
Join Jura Capital and Patrick Aisher, Chairman of Kinled Group, as we explore how Tivenix is positioning itself at the intersection of AI diagnostics, precision medicine, and scalable healthcare infrastructure.
4x–10x
Target return potential
50k CHF
Minimum investment
1m CHF
Total allocation
20%
Discount to Series A
5-yr
Target exit horizon
12 June
Allocation closes
Why this matters
Why earlier detection matters.
Alzheimer's disease and other neurodegenerative conditions affect millions of families globally, yet diagnosis often happens later than clinicians, healthcare systems, and families would ideally like.
Earlier detection has the potential to support better treatment pathways, improve patient identification for emerging therapies, and help healthcare providers make more informed decisions sooner.
As pharmaceutical companies continue investing heavily into neurodegenerative treatments, demand is growing for scalable diagnostic infrastructure capable of identifying disease earlier and more accurately.
For investors, this creates a significant commercial opportunity around the future of precision diagnostics.
The opportunity
The investment opportunity behind AI diagnostics.
Tivenix is a Swiss AI healthtech company focused on transforming how Alzheimer's disease is diagnosed, combining AI-driven analysis with proprietary biomarkers released by dying brain cells to support earlier and more accurate disease detection through a blood-based approach.
The opportunity extends beyond a single product. Tivenix is building scalable AI and biomarker infrastructure with potential future applications across multiple neurodegenerative diseases, including Parkinson's and Huntington's, at a moment when healthcare is shifting decisively toward precision medicine.
AI-powered blood-based diagnostics
Combining AI-driven analysis with cfDNA biomarkers to support earlier disease detection through a simple blood-based approach.
Proprietary cfDNA biomarker infrastructure
Patent-pending biomarker IP positioned to underpin a broader diagnostics platform rather than a single product.
Potential expansion beyond Alzheimer's
Architecture designed to extend across multiple neurodegenerative diseases including Parkinson's and Huntington's.
Companion diagnostic relevance
Pharmaceutical-grade diagnostics increasingly required to identify patients suitable for emerging therapies.
Strategic pharmaceutical demand
Scalable infrastructure aligned with the multi-billion-dollar investment cycle into neurodegenerative treatments.
Scalable healthcare infrastructure
Built for diagnostics groups, healthcare systems, and pharma, not a one-off clinical product.
Investment
Key investment highlights.
- Kinled-led investment round
- Supported by Danube BioVentures
- 20% discount to Series A
- Minimum investment: 50k CHF
- Total allocation: 1m CHF
- Allocation closes 12th June
- 5-year target exit horizon
- Target return potential: 4x–10x
- Strategic acquisition potential
Target returns are not guaranteed. Capital at risk.
The session
What we'll cover.
- 01The growing market opportunity in early disease detection
- 02How the Tivenix platform works
- 03The role of AI and cfDNA analysis in diagnostics
- 04Why companion diagnostics are becoming commercially important
- 05Commercial strategy and future growth plans
- 06The current investment opportunity
- 07Live Q&A with Patrick Aisher
Hosted by
Patrick Aisher
Chairman, Kinled Group
Patrick Aisher is Chairman of Kinled Group and is closely involved in leading the current Tivenix investment round alongside Danube BioVentures.
With experience across investment, company building, and healthcare innovation, Patrick will walk investors through the market opportunity, the commercial rationale behind the business, and how Tivenix is positioning itself within the evolving precision diagnostics market.
A wider relevance
A commercial opportunity with human relevance.
The commercial opportunity is significant, but the underlying challenge is deeply human. Neurodegenerative diseases create uncertainty for millions of families globally, often long before diagnosis becomes fully clear.
Earlier, more accessible detection has the potential to support better clinical decisions, improved treatment pathways, and more informed healthcare outcomes.
Tivenix sits within a broader shift toward earlier intervention, precision medicine, and AI-assisted healthcare infrastructure, an opportunity connected not only to commercial growth, but also to one of healthcare's most important evolving priorities.
Reserve
Reserve your webinar spot.
Join Jura Capital and Patrick Aisher for a private investor webinar exploring the future of AI diagnostics, precision medicine infrastructure, and the commercial opportunity behind earlier disease detection.
FAQ
Common questions.
Final word
Explore the future of AI diagnostics investing.
Join Jura Capital and Patrick Aisher to explore how precision diagnostics and AI infrastructure are reshaping the future of healthcare and creating new opportunities across private markets.
×This page is for informational purposes only and does not constitute investment advice, financial advice, or a recommendation to invest. Investments involve risk and may not be suitable for all investors. Target returns are not guaranteed and capital is at risk.